The importance of platelet activating factor in acute pancreatitis was examined by determining the tissue content of endogenous platelet activating factor and the protective effects of TCV-309, a highly selective platelet activating factor blocker, against caerulein induced pancreatitis in rats. Infusion of caerulein (10 Rg/ kg/h) for five hours resulted in about 70% increase in pancreatic weight, 22% rise in protein content, 50% reduction in tissue blood flow, nine fold increase in tissue level of platelet activating factor and 165% rise in plasma amylase as well as histological evidence of acute pancreatitis. Such infusion of caerulein in chronic pancreatic fistula rats caused a marked increase in protein output from basal secretion of 10 mg/30 minutes to 40 mg/30 minutes in the first hour of infusion followed by a decline in protein output to 15-20 mg/30 minutes in the following hours of the experiment. Exogenous platelet activating factor (50 tg/lkg) injected ip produced similar alterations in weight, protein content, blood flow, and histology of the pancreas but. the increment in serum amylase was significantly smaller and pancreatic secretion was reduced below the basal level. fig/kg) given ip before caerulein or platelet activating factor administration significantly reduced the biochemical and morphological alterations caused by caerulein and abolished those induced by exogenous platelet activating factor. These results indicate that platelet activating factor plays an important role in the pathogenesis of acute pancreatitis probably by reducing the blood flow and increasing vascular permeability in the pancreas.
kg/h) for five hours resulted in about 70% increase in pancreatic weight, 22% rise in protein content, 50% reduction in tissue blood flow, nine fold increase in tissue level of platelet activating factor and 165% rise in plasma amylase as well as histological evidence of acute pancreatitis. Such infusion of caerulein in chronic pancreatic fistula rats caused a marked increase in protein output from basal secretion of 10 mg/30 minutes to 40 mg/30 minutes in the first hour of infusion followed by a decline in protein output to [15] [16] [17] [18] [19] [20] mg/30 minutes in the following hours of the experiment. Exogenous platelet activating factor (50 tg/lkg) injected ip produced similar alterations in weight, protein content, blood flow, and histology of the pancreas but. the increment in serum amylase was significantly smaller and pancreatic secretion was reduced below the basal level. fig/kg) given ip before caerulein or platelet activating factor administration significantly reduced the biochemical and morphological alterations caused by caerulein and abolished those induced by exogenous platelet activating factor. These results indicate that platelet activating factor plays an important role in the pathogenesis of acute pancreatitis probably by reducing the blood flow and increasing vascular permeability in the pancreas. (Gut 1992; 33: 1268-1274) Acute pancreatitis is a severe disease with significant morbidity and mortality for which no specific treatment exists. Several experimental models of acute pancreatitis have been produced by various methods but one of the most frequently used involves an excessive stimulation of pancreatic secretion by the administration of supramaximal dose of caerulein"2or cholecystokinin octapeptide. 3 Caerulein induced pancreatitis represents a reproducible model suitable to study the effects of potentially ameliorating agents but the mechanism of the pancreatic damage has not been fully explained. The discharge of secretory proteins into the interstitial space because of excessive pancreatic stimulation and resulting oedema with accumulation of leucocytes are the major changes described in the caerulein induced pancreatitis. ' It has been reported4 that pancreatic acinar cells, stimulated by caerulein or cholecystokinin, release substantial amounts of platelet activating factor. Platelet activating factor is a low molecular weight phospholipid exhibiting potent biological effects including the platelet and neutrophil aggregation, systemic hypotension, pulmonary hypertension, and capillary leakageh leading to haemorrhagic damage in the gastrointestinal tract. 7 Emanuelli et al reported that an injection of platelet activating factor into the superior pancreaticoduodenal artery induced the changes in the rabbit pancreas characteristic of acute pancreatitis. These findings suggest that platelet activating factor may be involved in the progression of acute pancreatitis caused by infusion of caerulein but there is no experimental evidence so far to support this notion. Development of specific platelet activating factor blockers9 such as TCV-309'`has enabled us to examine the role of platelet activating factor in the pathogenesis of caerulein induced acute pancreatitis.
Methods

MATERIALS
Platelet activating factor (1-0-alkyl-2-0-acetylsn-glycero-3-phospho-choline) was purchased from Bachem Feinchemikalien AG (Bubendorf, Switzerland). The stock solution (in ethanol) was stored at -40°C. Working solution was made fresh daily. TCV-309 is 3-Bromo-5-[NphenylV\/N[2-( 1 ,2,3,4-tetrahydro-2-isoquinolylcarbonyloxy)ethyl]carbamoyl]-1 -propylpyridinium kindly provided as a gift by Dr Y Oka from Takeda Industries, Osaka, Japan. The aqueous solution was made fresh daily and used in the rats at a dose 10 times higher (50 [tg/kg) than that shown in separate experiments on these animals to reduce by 50% the platelet activating factor induced hypotension (ID50=5 [tg/kg ip).
The concentration of TCV-309 reducing by 50% platelet activating factor induced aggregation of human or rabbit platelets was found to be 10 7 M"' and this concentration was used in the in vitro studies on the dispersed pancreatic acini.
Male Wistar rats weighing 250-300 g, were used in this study to examine the pancreatic secretion and pancreatic blood flow during infusion of caerulein and to examine the involvement of platelet activating factor in the pathogenesis of acute pancreatitis.
EXAMINATION OF PANCREATIC SECRETION IN VIVO
Pancreatic secretion was examined in rats with chronic pancreatic fistula prepared as described previously."`Briefly, one polyethylene cannula was inserted into the common bile pancreatic duct to serve as the pancreatic fistula. This cannula was connected to another polyethylene cannula placed in the duodenum to permit the circulation of the pancreatic secretion into the duodenum. Both cannulae were brought to the exterior and protected by a stainless steel thimble allowing for the free movement of rats in their usual cages. During experiment they were placed in modified Bollman type cages to maintain the minimum restraint necessary. The metal thimble was removed, the cannulae were disconnected, the pancreatic cannula was used to collect the pure pancreatic juice, and the duodenal cannula was used for the reinfusion of the juice (diluted by saline 1:2) into the duodenum. The secretory studies usually started after six to eight days of recovery from the surgery usually after 12 hours of food but not water deprivation. The pancreatic secretion was collected from the pancreatic fistula in small preweighed vials in 30 minute aliquots to measure the volume flow and protein outputs as described previously." A duodenal cannula was used for the reinfusion of the collected pancreatic secretion (diluted by saline 1:2).
Several series of rats, each comprising six to eight animals, with chronic pancreatic fistula were used in secretory studies with the five hour return of pancreatic secretion to the duodenum. The following series were used; (i) sc infusion of saline (rate 1 ml/h) throughout the seven hour experiment; (ii) sc infusion of caerulein (10 Rg/ kg/h, rate 1 ml/h) throughout five hour period; (iii) ip injection of TCV-309 (50 [tg/kg) in 1 ml of saline) followed 90 minutes later by sc infusion of caerulein for the rest of experiment; (iv) ip administration of platelet activating factor (50 rig/kg) followed by sc infusion of saline for the duration of experiment; (v) ip injection of TCV-309 followed 30 minutes later by ip platelet activating factor and then by sc infusion of saline for the duration of experiment.
Rats used for studies with production of pancreatitis were allowed free access to water but no food for 18 total pancreatic blood flow. In a separate series of experiments, the progression of the changes in pancreatic blood flow was determined in rats anaesthetised with ether at 60 minute intervals twice before and five times during a five hour infusion of caerulein (10 ,ug/kg/h). In control tests, the blood flow was measured at 60 minute intervals during the seven hour infusion of saline.
The pancreatic blood flow was recorded in ml/ min/100 g tissue as displayed on the digital panel meter and presented either in absolute value or as per cent change from control value obtained in rats infused with saline.
Immediately after measurement of pancreatic blood flow, the vena cava was exposed and blood was drawn into a 2 ml plastic syringe containing 0.2 ml heparin (200 IU) (Polfa, Poland). Plasma amylase was determined by an enzymatic method using Bernfeld technique.'2 The values were expressed as units/litre.
HISTOLOGICAL EXAMINATION
The pancreas was then quickly dissected out from its attachment to the stomach, the duodenum, and the spleen, rinsed with saline, blotted on paper and weighed. Some pieces of pancreas were excised from the body portion, fixed in 10% formalin and stained with haematoxylin and eosin. The slides were examined histologically without the knowledge of the treatment given. The histologic grading of oedema was made using a scale ranging from 0 to 3; 0=no oedema, l=interlobular oedema, 2= interlobular oedema and moderate intralobular oedema, and 3=interlobular oedema and severe intralobular oedema. Leucocytic infiltration was graded from 0 (absent) to 3 for maximal alterations (diffuse infiltration in the entire pancreatic gland). Grading of vacualisation was based on the appropriate percentage of cell involved; 0=absent, l=less than 25%, 2=25-50%, and 3=more than 50%. was administered before the platelet activating factor injection (Fig 1) . Dispersed pancreatic acini obtained from rats infused for five hours with sc caerulein or given ip platelet activating factor showed usual dose response to caerulein added to the incubation medium in gradually increased concentrations (Table I ). The maximal amylase response to caerulein of acini from saline (control) treated rats was achieved at 10-1 1 M of caerulein, while that obtained from animals infused for five hours with caerulein, it occurred at 1V0-' M of caerulein. Similar shift to the right ofthe amylase response curve to caerulein was observed when the dispersed pancreatic acini were obtained from rats infused with caerulein plus TCV-309 or injected with platelet activating factor. The volume of pancreatic acini isolated from the saline treated rats was about 2 2 (0 3) ml per pancreas, whereas that from the rats infused with caerulein and injected with platelet activating factor it was significantly (p<005) lower and declined to about 0 8 (O 1) ml and 0 9 (0 2) ml, respectively. The volume of the acini obtained from rats infused with caerulein plus TCV-309 was also significantly reduced but that from platelet activating factor plus TCV-309 was not different from saline controls (Table I) (Fig 2) and the protein content by 22% and 18%, respectively (Fig 3) . Plasma amylase concentrations rose by about 165% in rats infused with caerulein and 110% after injection of platelet activating factor (Fig 4) . Histological changes such as oedema, cell infiltration, and vacualisation of acinar cells closely correlated the biochemic findings (Table II) . In rats infused with caerulein, the interlobular oedema and moderate intralobular oedema were accompanied by perivascular infiltration of leucocytes and the presence of vacuolisation in over 50% of acinar cells. In rats given platelet activating factor, both oedema and leucocyte infiltration were less pronounced and the vacuolisation was observed in less than 25% of acinar cells (Table II) . Pancreatic blood flow as measured by laser Doppler flowmetry at the end of a five hour infusion of caerulein or five hours after injection of platelet activating factor was reduced by about 50% (Fig 5) . As shown in Figure 6 , the pancreatic blood flow measured in saline perfused control animals anaesthetised with ether was relatively well sustained throughout the experiments. In rats receiving sc caerulein, the blood flow was significantly (p<005) reduced by about 43% after two hours of caerulein infusion and then showed only small further decrease during the remaining hours of the experiment.
Pretreatment with TCV-309 before caerulein infusion significantly reduced the increase in pancreatic weight (Fig 2) , protein content (Fig 3) and plasma concentration of amylase (Fig 4) but all these parameters were significantly (p<O 05) raised above the controls obtained from rats infused with saline. The fall in the pancreatic blood flow caused by caerulein was completely reversed by the pretreatment with TCV-309 ( Fig  5) . The pancreas appeared somewhat swollen and enlarged but peritoneal fluid was minimal. Cellular infiltration was significantly reduced but the extent of vacuolisation was not significantly different from that observed in animals infused with caerulein alone without pretreatment with TCV-309 (Table II) . by a marked rise in plasma amylase concentration similar to these reported earlier after intravenous Pretreatment with TCV-309 before the infusion.-2In their detailed study, the maximal administration of platelet activating factor increase in pancreatic weight was found after five almost completely prevented the alterations in to six hours of caerulein infusion and the optimal pancreatic weight, protein content, and blood dose of sc infused caerulein to achieve oedemaflow caused by platelet activating factor (Figs tous pancreatitis was 5-10 Rg/kg/h. In this study [2] [3] [4] [5] . The pancreas appeared normal and histo-we also used the technique of continuous sc logically only small oedema and cellular infiltra-infusion of caerulein at a dose of 10 rig/kg/h for tion or acinar cell vacuolisation were noticed five hours and this resulted in the increase in the (Table II) . Plasma concentration of amylase was pancreatic weight and the morphological alteranot different from the control value (Fig 4) .
tions of pancreatitis comparable with that Pancreatic tissue obtained from intact rats reported by Robert et al. infused with saline for five hours released only Our study describes for the first time the minute amounts of platelet activating factor (1.6 secretory and circulatory changes occurring with (0.9) pg/100 mg of wet tissue). Pancreatic speci-the progression of pancreatitis induced by mens from rats infused sc with caerulein showed caerulein infusion. Pancreatic protein secretion about nine-fold increase in the content of platelet in chronic pancreatic fistula rats infused with activating factor (13-9 (5 5) pg/100 mg). In rats caerulein at supramaximal dose, that was used to pretreated with TCV-309 plus caerulein,,the induce the pancreatitis, showed a sudden rise, content of pancreatic platelet activating factor almost immediately after the start of infusion, was significantly (p<005) smaller (4.5 (1 .6) pg/ reaching peak that was followed in the next hours 100 mg) than in those treated with caerulein by a marked decline to the level only slight above alone but about three times higher than in saline the baseline. As the severity of histological treated rats.
changes in the pancreas in response to caerulein such as the vacuolisation of acinar cells and the rise in plasma amylase concentrations were Discussion already significant at the third hour of infusion,3
This study confirms that subcutaneous infusion it is obvious that the decline in the exocrine of caerulein induced acute oedematous pan-secretory activity might be attributed to the creatitis that was accompanied by a marked damage of acinar cells. The vacuoles appearing increase in the content of endogenous platelet in these cells during infusion of caerulein contain activating factor in the pancreatic tissue and activated lysosomal enzymes which in turn may shows that the pretreatment with highly specific activate the digestive enzymes leading to cell and potent platelet activating factor blocker destruction and presumably to leakage of these enzymes into the interstitial tissue (where they produce inflammation) and into the blood.' our experience the pancreatic blood flow in Figure 5 : Pancreatic bloodflow in experiments as in Figure 2 .
caerulein induced pancreatitis is significantly Some of the effects of caerulein infusion have eas by caerulein leads to an been reproduced in this study by exogenous ontent of platelet activating platelet activating factor and the results indicate icreatic tissue and that the that platelet activating factor administered in a h platelet activating factor single dose by itself can induce pancreatitis with is excessive secretory stimula-typical enlargement of the pancreas and inflamand significantly ameliorates matory changes in the tissue as well as in the irculatory, and morphological increase in plasma amylase concentration. in induced pancreatitis. These Platelet activating factor also caused a marked lat platelet activating factor decrease in the pancreatic blood flow comparable with that observed after caerulein infusion. These changes induced by platelet activating factor can be almost completely reversed by the pretreatment with highly specific and potent platelet activating factor receptor blocker, TCV-309. Similar pancreatic injury was reported after TSaline the administration of platelet activating factor directly to the superior pancreaticoduodenal artery of rabbit.22 The pretreatment with a platelet activating factor blocker in this study also prevented the development of morphologic changes in the pancreatic tissue and the increment in plasma amylase concentration. These * v results support the concept that platelet activat-*,> _ ing factor is capable of inducing pancreatitis Caerulein * similar to that observed after infusion of caerulein and that it is mediated by specific platelet activating factor receptors.
There are, however, some differences in the action of caerulein and platelet activating factor on the pancreas. Although platelet activating factor is capable of stimulating enzyme secretion * 50 * 2 14 from the isolated acinar cells,2 according to our 8 10 12 14 results, it actually inhibits this secretion in vivo iods and this inhibition can be reversed by the tline (control) or caerulein pretreatment with TCV-309. It is likely that the erisk indicates significant decrease inhibition is mediated, at least in part, by the reduction in the pancreatic blood flow which is a a well known limiting factor in exocrine pancreatic secretion.23 Furthermore, pretreatment with a platelet activating factor blocker, which completely prevented the development of biochemical and morphological manifestation of platelet activating factor induced pancreatitis, only partly reduced the alterations involved in pancreatitis provoked by caerulein. This suggests that caerulein induces more severe pancreatitis than platelet activating factor and that, in addition to platelet activating factors, other mediators are probably involved in the pathogenesis of this pancreatitis. As the administration of platelet activating factor was reported to increase the release of leukotriene C4 4 that is known to cause a potent vasoconstriction,23 it is likely that both platelet activating factor and LTC4 play a synergistic role in the pathogenesis of acute pancreatitis.
I Lampel M, Kern HF. Acute interstitial pancreatitis in the rat
